Suvorexant Psychoeducation for Adults with Insomnia
Overview and Indication
Suvorexant (Belsomra) is an orexin receptor antagonist indicated for treating insomnia characterized by difficulties with sleep onset and/or sleep maintenance, with particular efficacy for sleep maintenance insomnia. 1, 2
The medication works by blocking wake-promoting neuropeptides (orexin A and B) from binding to their receptors (OX1R and OX2R), thereby suppressing the wake drive rather than inducing sedation through traditional mechanisms. 2
Dosing Instructions
Standard Dosing
- Recommended starting dose: 10 mg once nightly 2
- Take within 30 minutes of going to bed with at least 7 hours remaining before planned awakening 2
- Maximum dose: 20 mg once nightly 2
- If 10 mg is well-tolerated but ineffective, may increase to 15 mg or 20 mg 2
Timing and Food Considerations
- Avoid taking with or soon after meals, as food delays time to effect by approximately 1.5 hours 2
- Peak concentrations occur at median 2 hours (range 30 minutes to 6 hours) under fasted conditions 2
Special Population Adjustments
Obese females require particular caution:
- Exposure (AUC) increases by 46% and peak levels (Cmax) by 25% compared to non-obese females 2
- Consider this increased exposure risk before dose escalation 2
General obesity considerations:
- AUC and Cmax increase by 31% and 17% respectively in obese patients (BMI >30 kg/m²) 2
Female patients:
- AUC increases by 17% and Cmax by 9% compared to males 2
- Generally no dose adjustment needed based on gender alone 2
Elderly patients:
- No dose adjustment required based on age alone 2
Drug interactions:
- With moderate CYP3A inhibitors: Use 5 mg dose (generally should not exceed 10 mg) 2
- Not recommended with strong CYP3A inhibitors 2
CNS depressant combinations:
- Dosage reduction of suvorexant and/or other CNS depressants may be necessary due to additive effects 2
Contraindications
Absolute contraindication: Narcolepsy 2
This contraindication exists because orexin receptor antagonism can produce narcolepsy-like symptoms, as genetic mutations in the orexin system cause hereditary narcolepsy in animals and loss of orexin neurons occurs in humans with narcolepsy. 2
Safety Considerations and Warnings
CNS Depression and Daytime Impairment
- Can impair daytime wakefulness even when used as prescribed 2
- Impairment may occur without obvious symptoms and cannot be reliably detected by routine clinical examination 2
- CNS depressant effects may persist for several days after discontinuation 2
- Driving ability was impaired in some individuals taking 20 mg 2
- Discontinue or decrease dose if daytime somnolence develops in patients who drive 2
Common Adverse Events
The most frequently reported adverse event is somnolence (13% vs 3% placebo), with number needed to harm (NNH) of 13 for higher doses (40/30 mg) and 28 for lower doses (20/15 mg). 3, 4
Other common adverse effects include: 5
- Headache
- Dizziness
- Diarrhea
- Cough
- Abnormal dreams
- Upper respiratory tract infection
- Fatigue
- Back pain
- Dry mouth
Serious Adverse Events
Important safety note: Hallucinations, suicidal ideation/behavior, and motor vehicle accidents did not differ significantly between suvorexant and placebo in clinical trials. 6
However, potential concerns include: 7
- Signs of muscle weakness
- Weird dreams
- Sleep walking and other nighttime behaviors
- Suicidal ideation (monitor appropriately)
Long-term Safety Profile
- Generally safe and well-tolerated over 1 year of nightly treatment 4
- No evidence of rebound insomnia or withdrawal effects when discontinued after 3 or 12 months of use 3, 4
- Serious adverse events occurred in 5% of suvorexant patients vs 7% of placebo patients over 1 year 4
Efficacy Profile
Sleep Maintenance (Primary Indication)
The American Academy of Sleep Medicine suggests using suvorexant specifically for sleep maintenance insomnia based on trials of 10,15/20, and 20 mg doses. 1
Objective Improvements at Month 1
- Subjective total sleep time: +38.7 minutes vs +16.0 minutes placebo (difference 22.7 minutes) 4
- Subjective time to sleep onset: -18.0 minutes vs -8.4 minutes placebo (difference -9.5 minutes) 4
- Number needed to treat (NNT) for ≥6 point improvement on Insomnia Severity Index: 8 for both higher and lower dose regimens 3
Comparative Efficacy
Recent network meta-analysis shows suvorexant demonstrates efficacy across all measured outcomes, though effect sizes may be somewhat smaller compared to other dual orexin receptor antagonists like lemborexant and daridorexant. 8
Pharmacokinetic Properties
- Half-life: approximately 12 hours 2
- Steady-state achieved by day 3 2
- Extensively protein-bound (>99%) 2
- Primarily metabolized by CYP3A (minor contribution from CYP2C19) 2
- Elimination: 66% feces, 23% urine 2
- Does not prolong QTc interval to any clinically relevant extent 2
Clinical Pearls and Pitfalls
Key Advantages
- Novel mechanism of action (wake suppression rather than sedation induction) 9
- Theoretically lower addiction liability compared to benzodiazepines and Z-drugs 9
- Does not adversely affect sleep architecture 8
- No physiological tolerance, withdrawal symptoms, or rebound insomnia with abrupt discontinuation 8
Common Pitfalls to Avoid
- Taking with food: Delays onset by 1.5 hours, reducing effectiveness 2
- Insufficient time in bed: Must have at least 7 hours remaining before planned awakening 2
- Overlooking obesity status: Particularly in females, where exposure increases substantially 2
- Combining with strong CYP3A inhibitors: Not recommended due to excessive drug exposure 2
- Ignoring next-day effects: Monitor for daytime somnolence, especially in patients who drive 2
Patient Counseling Points
- Take only when able to get a full night's sleep (≥7 hours) 2
- Take on empty stomach for optimal effect 2
- Avoid alcohol and other CNS depressants 2
- Report any unusual nighttime behaviors, daytime sleepiness, or mood changes 7
- Do not drive or operate machinery if experiencing daytime somnolence 2
- Medication may take 2-3 days to reach steady-state effectiveness 2